Transforming the Epigenome

We develop first-in-class therapeutics targeting epigenetic alterations to treat cancer through revolutionary reprogramming approaches.

About 199 Bio

199 Biotechnologies is at the forefront of cancer reprogramming technology. Our first-in-class therapeutic approach targets cancer through novel epigenetic mechanisms, fundamentally changing how we treat this disease while exploring broader implications for human health.

The Aging Problem

Age-related diseases, particularly cancer, represent one of healthcare's greatest challenges, with brain cancers being among the most difficult to treat effectively.

1.

Current Treatments Fall Short

Traditional cancer treatments focus primarily on cell death rather than reprogramming, often leading to resistance and recurrence. This approach leaves patients vulnerable to disease progression and diminished quality of life.

2.

The Root Cause

The epigenome, which regulates gene expression, undergoes profound alterations in cancer cells. These changes drive tumor growth, invasion, and therapy resistance, making it crucial to address these fundamental changes.

3.

Lack of Targeted Solutions

Despite growing recognition of cancer's epigenetic nature, there is currently a lack of treatments that effectively reprogram cancer cells to restore normal function while being cancer-specific.

The rising cost and burden of care in the global healthcare system

2.1B

People that will be 60+ by 2050

10%

Global GDP spent on treatment costs

86%

Adults over 65 have at least 1 chronic disease

$37T

Value of a therapy that slows aging by just 1 year

References:
1. WHO: Aging and health
2. The economic value of targeting aging

Our approach

1.

Cancer-Specific Reprogramming

We've developed a revolutionary approach to cancer treatment through epigenetic reprogramming that specifically targets cancer cells. Our technology uniquely induces senescent apoptosis naturally in cancer cells, representing a first-in-class therapeutic strategy.

2.

Comprehensive Cancer Control

Our therapeutic approach simultaneously addresses multiple aspects of cancer biology. Through our innovative technology, we target cancer growth and proliferation, invasion and migration, metastatic potential, while inducing natural senescent anaphylaxis and effectively targeting cancer stem cells.

3.

Focus on Brain Cancer

While our technology works across multiple cancer types, we prioritize brain cancer due to its particular challenges and limited treatment options. Our approach shows promising results in this traditionally difficult-to-treat area.

Cancer Reprogramming

Overview

Our cancer reprogramming technology represents a first-in-class therapeutic approach that specifically targets cancer cells through epigenetic mechanisms. This innovative strategy aims to reprogram cancer cells while sparing healthy tissue.

High Impact

Our approach demonstrates unprecedented effects across multiple cancer cell lines, with particular efficacy in brain cancer models. By modulating specific epigenetic pathways, we can:

Reverse malignant cellular programming
Induce natural senescent anaphylaxis
Target therapy-resistant cancer cells
Prevent metastasis
Control tumor growth and invasion

Broad Effects

Epigenetic rejuvenation impacts multiple hallmarks of aging, including:

Genomic Stability: Reduces DNA damage and enhances DNA repair mechanisms.
Proteostasis: Improves protein folding, reduces protein aggregation, and enhances autophagy.
Mitochondrial Function: Restores mitochondrial efficiency, reducing oxidative stress and improving energy production.
Cellular Senescence: Decreases the number of senescent cells, reducing chronic inflammation and promoting tissue regeneration.
Stem Cell Function: Enhances the function and proliferative capacity of stem cells, supporting tissue repair and regeneration.

Platforms

Our delivery strategy consists of mRNA delivery and cell therapy. Our mRNA platform is well-established, with ongoing experiments focused on optimizing delivery techniques for maximum efficacy. Similarly, our cell therapy platform uses viral vectors, honing in on yield optimization, better promoter usage, and improved tropism to enhance the delivery and effectiveness of our reprogramming therapies.

mRNA

Our mRNA platform represents the cutting edge of therapeutic delivery technology. We've developed novel delivery vehicles based on phase separation technology, enabling precise and efficient delivery of reprogramming factors to cancer cells. This innovative approach ensures targeted delivery while minimizing off-target effects, representing a significant advancement in cancer therapeutic delivery.

Cell Therapy

Our cell therapy platform complements our mRNA approach, providing an additional avenue for delivering cancer reprogramming factors. We've optimized this platform for maximum efficacy and safety in targeting various cancer types, particularly focusing on brain cancer applications. Our cell therapy approach leverages advanced engineering techniques to ensure precise targeting and optimal therapeutic outcomes.

Organ-on-a-Chip

Our organ-on-a-chip technology simulates human organ systems in vitro, providing a platform to study the effects of epigenetic rejuvenation in a controlled environment. This innovation accelerates our understanding and optimization of reprogramming therapies, enabling high-throughput screening and detailed mechanistic studies.

Pipeline

Indication

Drug

Progress

-

Cancer

E-ON-001

Pre-clinical / In-vivo

-

Cancer

E-ON-002

Pre-clinical

-

Neurology/Vasculature

E-NE-001

Pre-clinical / In-vivo

-

Publications

Great minds, behind great things

Boris Djordjevic

CEO & Founder

Boris is the founder and CEO of 199 Biotechnologies and 199 Clinic, dedicated to translating research in partial reprogramming, gene therapies, and preventive and longevity medicine into clinical products.

Emad Moeendarbary

Chief Scientific Officer

Mechanical Engineer and Professor of Mechanobiology at University College London (UCL) and Principal Cancer Research UK Investigator, Emad has made significant strides in cell mechanics during his research at UCL, London Centre for Nanotechnology, University of Cambridge, and Massachusetts Institute of Technology.

Joao Pedro de Magalhaes

Scientific Advisor

Chair of Molecular Biogerontology at the University of Birmingham, leads the Genomics of Ageing and Rejuvenation Lab, focusing on genomic approaches to ageing; he holds a PhD from the University of Namur and completed a postdoc with Prof George Church at Harvard Medical School; with over 100 publications and numerous invited talks, his pioneering research in gene networks and long-lived species genomes aims to develop interventions to improve health and combat age-related diseases.

We are looking for...

Senior Scientist in Cell Biology

Lead projects focusing on genetics, lipofection, and RNA therapy to advance our aging and regenerative medicine goals. Requires 5+ years of experience with expertise in genetic engineering and cellular reprogramming.

Senior Scientist in Bioinformatics

Develop and apply bioinformatics, ML, and AI tools for analyzing genomic data related to aging and gene therapy. Must have proficiency in Python and R, with 5+ years of relevant experience.

Laboratory Technician

Support research activities by maintaining lab equipment, preparing samples, and conducting experiments. Requires 2+ years of lab experience and knowledge of molecular biology techniques.